MAGNETIC SECTOR FIELD HIGH RESOLUTION INDUCTIVELY-COUPLED MASS SPECTROMETER

申请经费用于资助Finnigan Element2型磁场高分辨率电感耦合等离子体质谱计（HR-ICP/MS）。Element2是可用于高分辨率多元素/同位素鉴定和定量的最灵敏的分析仪器。所要求的仪器将作为最先进的生物分析核心资源，为哈佛医学院(HMS)/哈佛公共卫生学院（HSPH）需要痕量/超痕量分析能力的各种生物医学、金属学和金属蛋白生物化学应用的高效、创新生物医学研究人员提供服务。磁扇区场技术取代了基于四极杆的系统，提供了明确的质量分辨率、多元素/同位素灵敏度、无多原子干扰检测和高通量性能，是地球化学、材料科学和半导体工业中高分辨率多元素/同位素应用的公认标准。这项技术在生物医学研究中的应用才刚刚开始，可以进行金属学分析、同位素比例稀释/示踪实验、临床毒理学/生物标志物流行病学分析，这些都是以前无法实现的。世界上很少有HR-ICP/MS仪器专门用于生物医学/金属学研究，美国也没有。所要求的仪器将作为设在波士顿布里格姆妇女医院的机构间合作核心资源加以利用。该仪器将由一个在生物医学痕量金属分析（包括ICP/MS）方面拥有20多年经验/专业知识的分析团队操作。该设施将致力于HMS/HSPH系统内的生物医学金属学研究，并将为其他区域机构的研究人员提供服务。仪器选址利用靠近主要核心设施，包括微量金属实验室（HSPH），哈佛医学院（HMS），哈佛遗传与基因组学中心，哈佛神经疾病中心，老化，遗传和神经变性中心，以及塔普林生物质谱分析设施（HMS）。主要用户群包括细胞/分子生物学、金属蛋白生物化学、生理学、环境毒理学和流行病学、生物金属代谢/体内平衡、眼科学、泌尿学、胃肠病学和神经精神病学等前沿领域的跨学科团队。该仪器的收购将推动阿尔茨海默病、炎症和肿瘤疾病、白内障、神经发育、高血压和环境毒理学的前沿研究。首席研究员和咨询委员会将促进整个地理区域的研究人员公平获得仪器和具有成本效益的利用。我们预计，这一核心设施资源将催化生物医学金属学的发现，并加速在这一新领域的前沿建立卓越中心。

DESCRIPTION (provided by applicant): (REVISED ABSTRACT) Funds are requested for a Finnigan Element2 magnetic sector field high-resolution inductively coupled plasma mass spectrometer (HR-ICP/MS). The Element2 is the most sensitive analytical instrument available for high-resolution multi-elemental/isotopic identification and quantitation. The requested instrument will serve as a state-of-the-art bioanalytical core resource for a diverse network of highly productive, innovative biomedical researchers at Harvard Medical School (HMS)/Harvard School of Public Health (HSPH) who require trace/ultra-trace analytical capabilities for a wide range of biomedical, metallomic, and metalloprotein biochemistry applications. Magnetic sector field technology supercedes quadrupole-based systems and provides unequivocal mass resolution, multi-elemental/isotopic sensitivity, polyatomic interference-free detection, and high-throughput performance and is the accepted standard for high resolution multi-elemental/isotopic applications in geochemistry, material science, and the semiconductor industry. Utilization of this technology in biomedical research is just beginning and allows metallomic assays, isotopic ratio dilution/tracer experiments, clinical toxicology/biomarker epidemiology analyses that have not been previously achievable. Very few HR-ICP/MS instruments are dedicated to biomedical/metallomic research anywhere in the world and none in the US. The requested instrument will be utilized as an inter-institutional cooperative core resource located at the Brigham & Women's Hospital, Boston. The instrument will be operated by an analytical team with over two decades of experience/expertise in biomedical trace metal analysis, including ICP/MS. The facility will be dedicated to biomedical metallomic research within the HMS/HSPH system and will be available to researchers at other regional institutions. Instrument siting capitalizes on proximity to major core facilities including the Trace Metal Laboratbry (HSPH), Harvard Institute of Medicine (HMS), Harvard Center for Genetics & Genomics, Harvard Center for Neurological Diseases, the Center for Aging, Genetics and Neurodegeneration, and the Taplin Biological Mass Spectrometry Facility (HMS). The Major Users Group includes interdisciplinary teams at the forefront of research in cellular/molecular biology, metalloprotein biochemistry, physiology, environmental toxicology and epidemiology, biometal metabolism/homeostasis, ophthalmology, urology, gastroenterology, and neuropsychiatry. Acquisition of this instrument will propel cutting-edge research in Alzheimer's disease, inflammatory and neoplastic diseases, cataracts, neurodevelopment, hypertension, and environmental toxicology. The principal investigator and Advisory Committee will promote equitable instrument access and cost-effective utilization to researchers throughout the geographic region. We anticipate that this core facility resource will catalyze discovery in biomedical metallomics and accelerate establishment of a Center of Excellence at the forefront of this new field.